Literature DB >> 11162945

Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings.

I Persson1.   

Abstract

Estrogens along with progesterone/progestins, and other hormones, are important determinants of cancer in the breast, endometrium and ovary. Estrogens may increase the risk of breast cancer through various mechanisms and at various phases of life, with a possible synergistic effect of progesterone/progestins. Exposure to high doses of placental hormones, such as estrogens and/or progesterone, during pregnancy may play a pivotal role in reducing subsequent breast cancer susceptibility. Estrogens cause endometrial cancer, an effect that can be reduced, prevented or reversed by progesterone/progestin - if allowed to act for a sufficiently long period of each cycle. The role of sex hormones seems important for ovarian carcinogenesis. Intake of combined oral contraceptives has a substantial and well-documented protective effect on endometrial and ovarian cancer risks. Epidemiological observations and experimental data from an animal model indicate that estrogens may have an adverse effect, while progesterone/progestins have a risk reducing effect directly on the ovarian epithelium. Thus, estrogens and other sex hormones have potential effects on the three most important female cancers. Research has yet to define how some of the risk factors can be modified or treatment regimens can be improved to reduce these cancer risks.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11162945     DOI: 10.1016/s0960-0760(00)00113-8

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  57 in total

Review 1.  Nutrition and survival after the diagnosis of breast cancer: a review of the evidence.

Authors:  Cheryl L Rock; Wendy Demark-Wahnefried
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

2.  CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies.

Authors:  Ming Yin; Jingrong Yan; Sheng Wei; Qingyi Wei
Journal:  Carcinogenesis       Date:  2010-02-22       Impact factor: 4.944

3.  An association between a common variant (G972R) in the IRS-1 gene and sex hormone levels in post-menopausal breast cancer survivors.

Authors:  Jing Fan; Roberta McKean-Cowdin; Leslie Bernstein; Frank Z Stanczyk; Arthur Xuejun Li; Rachel Ballard-Barbash; Anne McTiernan; Richard Baumgartner; Frank Gilliland
Journal:  Breast Cancer Res Treat       Date:  2006-06-05       Impact factor: 4.872

Review 4.  Natural products as aromatase inhibitors.

Authors:  Marcy J Balunas; Bin Su; Robert W Brueggemeier; A Douglas Kinghorn
Journal:  Anticancer Agents Med Chem       Date:  2008-08       Impact factor: 2.505

5.  N-acetylcysteine blocks formation of cancer-initiating estrogen-DNA adducts in cells.

Authors:  Muhammad Zahid; Muhammad Saeed; Mohammed F Ali; Eleanor G Rogan; Ercole L Cavalieri
Journal:  Free Radic Biol Med       Date:  2010-05-31       Impact factor: 7.376

6.  Dietary iron intake and risk of endometrial cancer: a population-based case-control study in Shanghai, China.

Authors:  Asha R Kallianpur; Sang-Ah Lee; Wang-Hong Xu; Wei Zheng; Yu-Tang Gao; Hui Cai; Zhi-Xian Ruan; Yong-Bing Xiang; Xiao Ou Shu
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

7.  Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer.

Authors:  Omar Khalid; Sanjeev K Baniwal; Daniel J Purcell; Nathalie Leclerc; Yankel Gabet; Michael R Stallcup; Gerhard A Coetzee; Baruch Frenkel
Journal:  Endocrinology       Date:  2008-08-28       Impact factor: 4.736

8.  A decade's difference: 10-year change in insomnia symptom prevalence in Canada depends on sociodemographics and health status.

Authors:  Sheila N Garland; Hillary Rowe; Lily M Repa; Ken Fowler; Eric S Zhou; Michael A Grandner
Journal:  Sleep Health       Date:  2018-02-19

9.  Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1.

Authors:  Kurt J Sales; Vivien Grant; Ian H Cook; David Maldonado-Pérez; Richard A Anderson; Alistair R W Williams; Henry N Jabbour
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

10.  Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival.

Authors:  K Einarsdóttir; H Darabi; K Czene; Y Li; Y L Low; Y Q Li; C Bonnard; S Wedrén; E T Liu; P Hall; J Liu; K Humphreys
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.